Reference number : GC-2017-Q1-00434, amendment number : , agreement type : G, recipient legal name : Hwang, Dae Kun (Ryerson University), recipient country : CA, recipient province : nan, recipient city : Ontario, recipient postal code : nan, program name english : Engage Grants for Universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : Mammalian cells used to produce various vaccines in bioreactors are typically grown on a support matrix_x000D_
termed a microcarrier, which can be made of a number of different materials including DEAE-dextran, glass,_x000D_
polystyrene plastic, acrylamide, collagen, and alginate. Commercial microcarriers are only available in smooth_x000D_
surface, spherical forms. Spheres have the smallest surface-area-to-volume ratio, and therefore the least surface_x000D_
space available for cells to attach for a given volume. In addition to their spherical shape, the smooth surface of_x000D_
available microcarriers makes it difficult to increase the surface area for cell culture capacity improvement._x000D_
Another challenge in current microcarrier-based cell culture is that the microcarrier surface needs to be_x000D_
chemically modified prior to cell attachment and detachment (recovery) - often involving expensive enzymes._x000D_
The Hwang group at Ryerson has developed a technique that can produce microcarriers with designed shapes_x000D_
and tuneable surface wrinkles that can significantly increase their surface area. When used for cell culture,_x000D_
these microcarriers can greatly improve cell attaching capacity. In addition, the microcarrier surface is not_x000D_
chemically modified, which simplifies the cell attaching and recovery process without using enzymes._x000D_
Sanofi Pasteur is a world leading vaccine manufacturing company, and its head office in Toronto has Canada's_x000D_
largest vaccine R&D facility. Sanofi manufactures several vaccines through mammalian cell culture using_x000D_
microcarriers. This Engage grant will enable Sanofi and the Ryerson team to begin working towards_x000D_
successfully integrating these non-spherical-microcarrier-based technologies into their vaccine production. As a_x000D_
result, cell culture efficiency and vaccine production at Sanofi can be significantly improved in the future., program purpose french : Mammalian cells used to produce various vaccines in bioreactors are typically grown on a support matrix_x000D_
termed a microcarrier, which can be made of a number of different materials including DEAE-dextran, glass,_x000D_
polystyrene plastic, acrylamide, collagen, and alginate. Commercial microcarriers are only available in smooth_x000D_
surface, spherical forms. Spheres have the smallest surface-area-to-volume ratio, and therefore the least surface_x000D_
space available for cells to attach for a given volume. In addition to their spherical shape, the smooth surface of_x000D_
available microcarriers makes it difficult to increase the surface area for cell culture capacity improvement._x000D_
Another challenge in current microcarrier-based cell culture is that the microcarrier surface needs to be_x000D_
chemically modified prior to cell attachment and detachment (recovery) - often involving expensive enzymes._x000D_
The Hwang group at Ryerson has developed a technique that can produce microcarriers with designed shapes_x000D_
and tuneable surface wrinkles that can significantly increase their surface area. When used for cell culture,_x000D_
these microcarriers can greatly improve cell attaching capacity. In addition, the microcarrier surface is not_x000D_
chemically modified, which simplifies the cell attaching and recovery process without using enzymes._x000D_
Sanofi Pasteur is a world leading vaccine manufacturing company, and its head office in Toronto has Canada's_x000D_
largest vaccine R&D facility. Sanofi manufactures several vaccines through mammalian cell culture using_x000D_
microcarriers. This Engage grant will enable Sanofi and the Ryerson team to begin working towards_x000D_
successfully integrating these non-spherical-microcarrier-based technologies into their vaccine production. As a_x000D_
result, cell culture efficiency and vaccine production at Sanofi can be significantly improved in the future., agreement title english : Wrinkled non-spherical microparticles as a new microcarrier for cell culture applications in Sanofi Pasteur, agreement title french : Wrinkled non-spherical microparticles as a new microcarrier for cell culture applications in Sanofi Pasteur, agreement number : EGP, agreement value : 25000.0, agreement start date : 2017-06-14, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year. (2017-2018 to 2018-2019), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier. (2017-2018 à 2018-2019), owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada